Ligand Takes Out Neurogen For At Least $11 Million
This article was originally published in The Pink Sheet Daily
Continuing its rebound from the Third Point fight, Ligand issues a sliver of stock to take control of Neurogen.
You may also be interested in...
Stock-for-stock exchange is valued at $70 million, though DARA future still unclear.
Company may also hire Ligand personnel in addition to purchase of Ontak, Targretin and Panretin.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.